WRN inhibitors-41(Synnovation Therapeutics)

Recent efforts have identified WRN helicase as a critical dependency in mismatch repair-deficient (dMMR) cancers. Small molecules targeting WRN demonstrate selective activity in microsatellite instability-high (MSI-H) models. These compounds impair tumor growth and promote cancer cell death by disrupting genome maintenance pathways, highlighting a promising therapeutic strategy for genetically defined, treatment-resistant tumors.